Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis
Frontiers in Public Health · 2024
DOI: 10.3389/fpubh.2024.1432947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2024. Verfasst von Zhaoyan Chen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Gallbladder Neoplasms, Deoxycytidine, Cost-Benefit Analysis, Gemcitabine. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The incidence of gall bladder cancer (GBC), one of the most prevalent bile duct malignancies, differs with ethnicity and geographic location. To treat unresected GBC in the Chinese setting, this study aimed to assess the financial effectiveness of a combination of modified gemcitabine and oxaliplatin.
Methods
Data from a randomized controlled study in which individuals with metastatic GBC were treated with oxaliplatin and gemcitabine demonstrated improved survival. A Markov model is built to calculate the incremental cost–benefit ratio (ICER) from the viewpoint of Chinese society on the basis of clinical symptoms and disease development. One-way certainty and probability sensitivity analyses are used to describe the uncertainty in the model.
Results
Compared with those of fluorouracil (FU) and folinic acid, the utility value of modified oxaliplatin combined with gemcitabine increased by 0.22QALY throughout the course of the 10-year simulation (FA). In a Chinese healthcare setting, the cost-effectiveness ratio (ICER) is $52765.59/QALY, with a 0% chance of cost–benefit at the WTP (willing-to-pay) level of $37697.00/QALY. The ICERs predicted by sensitivity analysis were not significantly affected by cost variations related to the management of Grade 3–4 AEs, the diagnostics used, or hospitalization expenditures.
Conclusion
In a Chinese healthcare context, modified gemcitabine coupled with oxaliplatin (mGEMOX) is not a cost-effective treatment option for unresectable GBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
Zitieren
APA
Chen, Z., & Tian, F. (2024). Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2024.1432947
Vancouver
Chen Z, Tian F. Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis. Frontiers in Public Health. 2024. doi:10.3389/fpubh.2024.1432947
BibTeX
@article{Chen2024,
author = {Chen, Zhaoyan and Tian, Fangyuan},
title = {Modification of gemcitabine with oxaliplatin in China for unresectable gallbladder cancer: a cost-effectiveness analysis},
journal = {Frontiers in Public Health},
year = {2024},
doi = {10.3389/fpubh.2024.1432947}
}
EUVIMED